The role of HLA-B27 in spondyloarthritis

Immunogenetics

Volumn 50, Issue 3-4, 1999, Pages 220-227

  Allen, Rachel L ^b   Bowness, Paul ^a   McMichael, Andrew J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b Dept of Pathology ^*  (United Kingdom)

Author keywords

Antigen presentation; Cys67; HLA B27; Spondyloarthropathy

Indexed keywords

HLA B27 ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; DISEASE ASSOCIATION; HISTOCOMPATIBILITY GENE; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPONDYLOARTHROPATHY; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TRANSGENIC ANIMAL;

EID: 0033367519     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510050596     Document Type: Review

References (86)

1. Allen RL, Gillespie GMA, Hall F, Edmonds S, Hall MA, Wordsworth B., McMichael AJ, Bowness P (1997) Multiple T cell expansions are found in the blood and synovial fluid of patients with reactive arthritis. J Rheumatol 24:1750-1757
2. Allen RL, O'Callaghan CA, McMichael AJ, Bowness P (1999) Cutting Edge: HLA B27 forms a novel heavy chain homodimer structure. J Immunol 162:5045-5048
3. Amor B, Kahan A, Georgiadis AE (1978) Transient loss of HLA B27. Lancet (i):284
4. Armas JB, Gonzalez S, Martinez-Borra J, Laranjeira F, Ribeiro E, Correia J, Ferreira ML, Toste M, Lopez-Vazquez A, Lopez-Larrea C (1999) Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles. Tissue Antigens 53:237-243
5. Archer JR, Whelan MA, Badakere SS, McLean IL, Archer IVJ., Winrow VR (1990) Effect of a free sulphydryl group on expression of HLA-B27 specificity. Scand J Rheum Suppl 87:44-50
6. Beacock-Sharp H, Young JL, Gaston JS (1998) Analysis of T cell subsets in the peripheral blood and synovial fluid of reactive arthritis patients. Ann Rheum Dis 57:100-106
7. Benjamin R, Parham P (1990) Guilt by association; HLA-B27 and ankylosing spondylitis. Immunol Today 11:137-142
8. Benjamin RJ, Madrigal A, Parham P (1991) Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 351:74-77
9. Boisgerault F, Mounier J, Tieng V, Stolzenberg M-C, Khalil-Daher I, Schmid M, Sansonetti P, Charron D, Toubert A (1998) Alteration of HLA-B27 peptide presentation after infection of transfected murine L cells by Shigella flexneri. Infect Immun 66:4484-4490
10. Bowness P, Allen RL, Barclay DN, Jones EY, McMichael AJ (1998) Importance of a conserved TCR Ja-encoded tyrosine for T cell recognition of an HLA B27/peptide complex. Eur J Immunol 28:2704-2713
11. Bowness P, Moss PA, Rowland-Jones S, Bell JI, McMichael AJ (1993) Conservation of T cell receptor usage by HLA B27-restricted influenza-specific cytotoxic T lymphocytes suggests a general pattern for antigen-specific major histocompatibility complex Class I-restricted responses. Eur J Immunol 23:1417-1421
12. Breban M, Hammer RE, Richardson JA, Taurog JD (1993) Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J Exp Med 178:1607-1616
13. Breban M, Fernandezsueiro JL, Richardson JA, Hadavand RR, Maika SD, Hammer RE, Taurog JD (1996) T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 156:794-803
14. Brewerton DA, Caffrey M, Hart FD, James DCO, Nichols A, Sturrock RD (1973) Ankylosing spondylitis and HL-A27. Lancet i:904-907
15. Brewerton DA, Caffrey M, Hart FD, James DCO, Nichols A, Sturrock RD (1974) Reiters disease and HL-A27. Lancet ii:996-998
16. Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell J, Wordsworth BP, Cornelis F (1996) HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 55:268-270
17. Brown M, Wordsworth P (1997) Predisposing factors to spondyloarthropathies. Curr Opin Rheumatol 9:308-314
18. Calin A, Marder A, Becks E (1983) Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. Arthritis Rheum 26:140
19. Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA (1994) Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. Immunity 1:121-130
20. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A (1998) Cutting edge: Human monomyelocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 160:3096-3100
21. D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zucarelli A, Bitti PP, Tosi R, Sorrentino R (1995) Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 25:3199-3201
22. Davenport M (1995) The promiscuous B27 hypothesis (letter). Lancet 346:500-501
23. Duchmann R, May E, Ackermann B, Goergen B, Meyer-zum-Buschenfelde KH, Marker-Hermann E (1996) HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacterial or self-antigens are dominated by closely related TCRBV gene segments, A study in patients with reactive arthritis. Scand J Immunol 43:101-108
24. Dulphy N, Peyrat M-A, Tieng V, Douay C, Rabian C, Tamouza R, Laoussadi S, Berembaum F, Chabot A, Bonneville M, Charron D, Toubert A (1999) Common intra-articular T cell expansions in patients with reactive arthritis: Identical β-chain junctional sequences and cytotoxicity toward HLA-B27. J Immunol 162:3830-3839
25. El-Zaatari FA, Sams KC, Taurog JD (1990) In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substitution of the side chain. J Immunol 144:1512-1517
26. Fiorillo MT, Meadows L, D'Amato M, Shabanowitz J, Hunt DF, Appela E, Sorrentino R (1997) Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 27:368-373
27. Gao XM, Wordsworth P, McMichael AJ (1994) Collagen-specific cytotoxic T lymphocyte responses in patients with ankylosing spondylitis and reactive arthritis. Eur J Immunol 24:1665-1570
28. Gao XM, Wordsworth P, McMichael AJ, Kyaw MM, Seifert M, Rees D, Dougan G (1996) Homocysteine modification of HLA antigens and its immunological consequences. Eur J Immunol 26:1443-1450
29. Garcia F, Marina A, Lopez de Castro JA (1997a) Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. Tissue Antigens 49:215-221
30. Garcia F, Galocha B, Villadangos JA, Lamas JR, Albar JP, Marina A, Lopez d Castro JA (1997b) HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. Tissue Antigens 49:580-587
31. Garcia F, Rognan D, Lamas JR, Marina A, Lopez de Castro JA (1998) An HLA-B27 polymorphism (B*2710) that is critical for T-cell recognition has limited effects on peptide specificity. Tissue Antigens 51:1
32. Genestier L, Paillot R, Bonnefoy-Berard N, Meffre G, Flacher M, Fevre D, Liu YJ, le Bouteiller P, Waldmann H, Engelhard V, Banchereau J, Revillard JP (1997) Fas-Independent apoptosis of activated T cells induced by antibodies to the HLA class I α1 domain. Blood 90:3629-3639
33. Hall FC, Bowness P (1996) HLA and disease: from molecular function to disease association? In: Browning M, McMichael AJ (eds) HLA and MHC genes, molecules and function. Bios Scientific Publishers, Oxford, pp353-381
34. Hammer RE, Maika SD, Richardson JA, Tang J-P, Taurog JD (1990) Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human b2m: an animal model of HLA-B27 associated disorders. Cell 63:1099-1112
35. Kassel AB, Pilling D, Reynolds D, Life PF, Bacon PA, Gaston JSH (1992) MHC restriction of synovial fluid lymphocyte responses to the triggering organism in reactive arthritis. Absence of a class I restricted response. Clin Exp Immunol 88:442-447
36. Hermann E, Yu DTY, zum Buschenfelde K-HM., Fleischer B (1993) HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 342:646-650
37. Huang F, Yamaguchi A, Tsuchiya N, Ikawa T, Tamura N, Virtala MM, Granfors K, Yasaei P, Yu DT (1997) Induction of alternate splicing of HLA-B27 by bacterial invasion. Arthritis Rheum 40:694-703
38. Huppertz HI, Heesemann J (1996) The influence of HLA B27 and interferon-gamma on the invasion and persistence of Yersinia in primary human fibroblasts. Med Microbiol Immunol 185:163-170
39. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC (1991) Identification of self peptides bound to purified HLA-B27. Nature 353:326-329
40. Jarvinen P (1995) Occurrence of ankylosing spondylitis in a nationwide series of twins. Arhritis Rheum 38:381-383
41. Jefferies WA, MacPherson GG (1987) Expression of the W6/32 HLA epitope by cells of rat, mouse, human and other species: critical dependence on the interaction of specific MHC heavy chains with human or bovine beta 2-microglobulin. Eur J Immunol 17:1257-1263
42. Kapasi K, Inman RD (1992) HLA-B27 expression modulates Gram-negative bacterial invasion into transfected L cells. J Immunol 148:3554-3559
43. Kapasi K, Inman RD (1994) ME1 epitope of HLA-B27 confers class I-mediated modulation of Gram-negative bacterial invasion. J Immunol 153:833-840
44. Keat A, Dixey J, Sonnex C, Thomas B, Osborn M, Taylor-Robinson D (1987) Chlamydia trachomatis and reactive arthritis: the missing link. Lancet (I):72
45. Kirveskari J, Kellner H, Wuorela M, Soini H, Frankenberger B, Leirisalo-Repo M, Weiss EH, Granfors K (1997) False-negative serological HLA-B27 typing results may be due to altered antigenic epitopes and can be detected by polymerase chain reaction. Br J Rheumatol 36:185-189
46. Khare SD, Luthra HS, David C (1995) Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin; a model of human spondyloarthropathies. J Exp Med 182:1153-1158
47. 2m. J Clin Invest 98:2746-2755
48. Khare SD, Bull MJ, Hanson J, Luthra HS, David CS (1998) Spontaneous Inflammatory Disease in HLA-B27 transgenic mice is independant of MHC Class II molecules. A direct role for B27 heavy chains and not B27-derived peptides. J Immunol 160:101-106
49. Khare SD, Lee S, Bull MJ, Hanson J, Luthra HS, Hammerling GJ, David CS (1999) Peptide binding alphalalpha2 domain of HLA-B27 contributes to the disease pathogenesis in transgenic mice. Hum Immunol 60:116-126
50. Lahesmaa R, Skurnik M, Granfors K, Mottonen T, Saario R, Toivanen A, Toivanen P (1992) Molecular mimicry in the pathogenesis of spondyloarthropathies. A critical appraisal of cross-reactivity between microbial antigens and HLA B27. Br J Rheum 31:221-229
51. Lahesmaa R, Soderberg C, Bliska J, Allsup A, Luukkainen R, Steinman L, Uchiyama T, Peltz G (1995) Pathogen antigen-and superantigen-reactive synovial fluid T cells in reactive arthritis. J Infect Dis 172:1290-1297
52. Laitio P, Virtala M, Salmi M, Pelliniemi LJ, Yu DT, Granfors K (1997) HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol 27:1331-1338
53. Life PF, Bassey EOE, Gaston JSH (1991) T-cell recognition of bacterial heat-shock proteins in inflammatory arthritis. Immun Rev 121:113-135
54. Lopez de Castro JA (1998) The pathogenetic role of HLA-B27 in chronic arthritis. Curr Opin Immunol 10:59-66
55. Lopez-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, Dominguez O, Coto E, Pena M, Setien F, et al. (1995) HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens 45:169-176
56. Luque I, Solana R, Galliani MD, Gonzalez R, Garcia F, Lopez de Castro JA, Pena J (1996) Threonine 80 on HLA B27 confers protection against lysis by a group of natural killer clones. Eur J Immunol 26:1974-1977
57. MacLean L, Macey M, Lowdell M, Badakere S, Whelan M, Perrett D, Archer J (1992) Sulphydryl reactivity of the HLA-B27 epitope: accessibility of the free cysteine studied by flow cytometry. Ann Rheum Dis 51:456-460
58. Madden DR, Gorga JC, Strominger JL, Wiley DC (1991) The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 353:321-325
59. Madden DR, Gorga JC, Strominger JL, Wiley DC (1992) The three dimensional structure of HLA-B27 at 2.1A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 70:1035-1048
60. Marker-Hermann E, Meyer zum Buschenfelde KH, Wildner G (1997) HLA-B27-derived peptides as autoantigens for T lymphocytes in ankylosing spondylitis. Arthritis Rheum 40:2047-2054
61. Maziarz RT, Fraser J, Strominger JL, Burakoff SJ (1986) The human HLA-specific monoclonal antibody W6/32 recognizes a discontinuous epitope within the alpha 2 domain of murine H-2Db. Immunogenetics 24:206-208
62. Mertz AK, Daser A, Skurnik M, Wiesmuller KH, Braun J, Appel H, Batsford S, Wu P, Distler A, Sieper J (1994) The evolutionarily conserved ribosomal protein L23 and the cationic urease beta-subunit of Yersinia enterocolitica O: 3 belong to the immunodominant antigens in Yersinia-triggered reactive arthritis: implications for autoimmunity. Mol Med 1:44-55
63. Neumuller J, Fischer M, Eberl R (1993) Failure of the serological determination of HLA-B27 due to antigen masking in patients with ankylosing spondylitis. Rheumatol Int 13:163-167
64. Ortiz-Alvarez O, Yu DT, Petty RE, Finlay BB (1998) HLA-B27 does not affect invasion of arthritogenic bacteria into human cells. J Rheumatol 25:1765-1771
65. Parham P (1996) Presentation of HLA class I-derived peptides: Potential involvement in allorecognition and HLA-B27-associated arthritis. Immunol Rev 154:137-154
66. Peh CA, Burrows SR, Barnden M, Khanna R, Cresswell P, Moss DJ, McCluskey J (1998) HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 8:531-542
67. Peruzzi M, Wagtmann N, Long EO (1996) A p70 killer cell inhibitory receptor for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705. J Exp Med 184:1585-1590
68. Rahman MU, Cheema MA, Schumacher HR, Hudson HP (1992) Molecular evidence for the presence of Chlamydia in the synovium of patients with Reiter's syndrome. Arthritis Rheum 35:521-529
69. Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH (1997) Possible protective role of HLA-B*2706 for ankylosing spondylitis. Tissue Antigens 49:67-69
70. Rötzschke O, Falk K, Stevanović S, Gnau V, Jung G, Rammensee HG (1994) Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 39:74-77
71. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM (1973) High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 288:704-706
72. Schwimmbeck PL, Yu DT, Oldstone MB (1987) Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 166:173-181
73. Scofield RH, Kurien B, Gross T, Warren WL, Harley JB (1995) HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 345:1542-1544
74. Simmons WA, Summerfield SG, Roopenian DC, Slaughter CA, Zuberi AR, Gaskell SJ, Bordoli RS, Hoyes J, Moomaw CR, Colbert RA, Leong LY, Butcher GW, Hammer RE, Taurog JD (1997) Novel HY peptide antigens presented by HLA-B27. J Immunol 159:2750-2759
75. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE (1993) Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 150:4168-4178
76. Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE (1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 180:2359-2364
77. Tieng V, Dulphy N, Boisgerault F, Tamouza R, Charron D, Toubert A (1997) HLA-B*2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics 47:103-105
78. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J (1997) A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 159:5715-5723
79. Urban RG, Chicz RM, Lane WS, Strominger JL, Rehm A, Kenter MJH, Uytdehaag FGCM, Ploegh H, Uchanska-Ziegler B, Ziegler A (1994) A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 91:1534-1538
80. Van Bohemen OG, Grumet FC, Zanen HC (1984) Identification of HLA B27 M1 and M2 cross-reactive antigens in Klebsiella, Shigella and Yersinia. Immunology 51:607-610
81. Virtala M, Kirveskari J, Granfors K (1997) HLA-B27 modulates the survival of salmonella enteriditis in transfected L cells possibly by impaired nitric oxide production. Infect Immun 65:4236-4242
82. Whelan MA, Archer JR (1993) Chemical reactivity of an HLA-B27 thiol group. Eur J Immunol 23:3278-3285
83. + T cells in chronic HIV infection are antigen specific. J Exp Med 188:785-790
84. Wucherpfennig KW, Strominger J (1995) Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80:95-705
85. Wuorela M, Jalkanen S, Kirveskari J, Laitio P, Granfors K (1991) Yersinia enterocolitica serotype O: 3 alters the expression of serologic HLA-B27 epitopes on human monocytes. Infect Immunity 65:2060-2066
86. Zhou M, Sayad A, Simmons WA, Jones RC, Maika SD, Satumtira N, Dorris ML, Gaskell SJ, Bordoli RS, Sartor RB, Slaughter CA, Richardson JA, Hammer RE, Taurog JD (1998) The specificity of peptides bound to human histocompatibility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J Exp Med 188:977-886